|Title / Titel||Estimate of potential antiviral activity of Etravirine in the SHCS based on genotypic drug resistance information.|
|Abstract (PDF, 14 KB)|
|Summary / Zusammenfassung||The emergence of drug resistance against one of the two available non nucleoside reverse transcriptase inhibitors (NNRTI) efavirenz (EFV)and nevirapine (NVP) induces always crossresistance against the other substance. Recently, the situation changed because etravirine (ETV), a novel NNRTI, has been demonstrated to exhibit a different resistance pattern, which does result only in partial crossresistance to EFV and NVP. Thus, in the future, despite failure of the NNRTI class, ETV may potentially still work in a considerable fraction of those patients. Detailed genotypic resistance patterns have been worked out for ETV. To date, however, it is not known what proportion of patients who have failed a NNRTI containing regimen, will be able to profit from ETV.
Thus, we propose to determine the prevalence of ETV-associated drug resistance mutations in drug naïve, in acutely and recently infected, drug experienced and specifically in NNRTI failing individuals in the SHCS using the SHCS genotypic drug resistance database. Furthermore, we will define the proportion of patients in all these strata, who - based on genotypic information – will be able to profit from this drug in the future. Such information is of immediate usefulness, particularly for patients having failed a conventional NNRTI containing regimen.
|Keywords / Suchbegriffe||HIV, NNRTI, etravirine, antiretroviral treatment|
|Project leadership and contacts /
Projektleitung und Kontakte
|Funding source(s) /
|SNF (Personen- und Projektförderung)
Swiss HIV Cohort Study
|Duration of Project / Projektdauer||Jan 2008 to Jun 2010|